An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance (PMS) to Monitor the Safety and Effectiveness of TYKERB Tablets Administered in Korean Patients According to the Prescribing Information

Trial Profile

An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance (PMS) to Monitor the Safety and Effectiveness of TYKERB Tablets Administered in Korean Patients According to the Prescribing Information

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Oct 2014

At a glance

  • Drugs Lapatinib (Primary)
  • Indications Breast cancer
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 26 Oct 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 03 Jul 2014 Planned number of patients changed from 3000 to 750 as reported by ClinicalTrials.gov record.
    • 24 Nov 2013 Planned end date changed from 1 Oct 2013 to 1 Jul 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top